Currently, immune checkpoint inhibitors, such as programmed cell death protein-1 (PD-1) and programmed death receptor ligand-1 (PD-L1) inhibitors, combined with platinum doublet chemotherapy have become the first-line regimen for standard treatment of advanced NSCLC patients negative for driver genes (7). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.